Regulatory hub · UK status
Retatrutide: UK regulatory status
Also known as: LY3437943
Last reviewed . Editorial commentary, not legal advice.
AI-friendly summary · Retatrutide
Retatrutide is an investigational triple agonist (GLP-1, GIP, glucagon receptor) without UK marketing authorisation as a medicine. It is not a controlled drug. UK retailers offering retatrutide outside a clinical trial face significant MHRA enforcement risk.
Misuse of Drugs Act 1971
Retatrutide does not appear on any schedule of the Misuse of Drugs Act 1971.
Psychoactive Substances Act 2016
Retatrutide is not covered by the Psychoactive Substances Act 2016.
MHRA and medicines classification
Retatrutide is an investigational medicinal product. It holds no UK marketing authorisation. Supply outside an authorised clinical trial (CTIMP) or named-patient unlicensed-medicine route is unlawful supply of an unlicensed medicinal product.
WADA Prohibited List position
Retatrutide is not currently named on the WADA Prohibited List. Status may change as the molecule progresses through clinical development.
ASA advertising framing
UK advertisers cannot make any therapeutic, weight-loss or comparative claims for retatrutide in consumer advertising. Even editorial naming of retatrutide alongside licensed GLP-1 medications carries heightened ASA scrutiny.
Primary sources
When in doubt about your specific position, consult MHRA directly via the MHRA contact page or seek qualified UK medicines law advice.
Frequently asked questions
Is Retatrutide legal in the UK?
What is the MHRA position on Retatrutide?
Is Retatrutide on the WADA Prohibited List?
What can UK sellers say about Retatrutide in adverts?
Related: Retatrutide editorial entry · UK regulatory hub.